Patient Enrollment. Any patient enrollment projections are good faith estimates and PPD shall exercise commercially reasonable efforts to meet such enrollment projections.
Patient Enrollment. For the avoidance of doubt, the parties understand and agree that enrollment rates set forth herein are good faith estimates only and PPD shall exercise all commercially reasonable efforts to meet enrollment expectations.
Patient Enrollment. Receipt of the initial applications with respect to each of the Programs, and application review, general program eligibility determination and enrollment functions with respect to each Program, shall be the responsibility of the applicable Nominated Agent.
Patient Enrollment. Customer shall use commercially reasonable efforts to persuade Eligible Patients to consent to receive CCM Services and to actually accept CCM Services each month from a Case Manager.
Patient Enrollment. The parties agree that enrollment numbers are good faith estimates and that various factors outside of PPD’s control can affect the rate of enrollment. PPD shall exercise all reasonable efforts to meet such enrollment estimates, but cannot guarantee that enrollment numbers or enrollment timelines will be met, provided however that the Sponsor shall not be responsible for delays in enrollment timelines as a result of PPD’s negligence or willful misconduct.
Patient Enrollment. Sponsor acknowledges and agrees that patient enrollment rates set forth in this Agreement or any Project Addendum are good faith estimates only and are not guarantees of patient enrollment with respect to the applicable Project. Although PPD shall not be responsible for patient enrollment with respect to any Project, PPD shall use reasonable diligence in providing the Services for such Project to assist Sponsor in meeting its patient enrollment expectations.
Patient Enrollment. Enrollment numbers are good faith estimates and Service Provider shall exercise all reasonable diligence to meet such enrollment estimates.
Patient Enrollment. Although enrollment numbers are good faith estimates, SciQuus shall exercise all reasonable diligent efforts to meet such enrollment estimates.
Patient Enrollment. Acuity has enrolled not less than ten (10) human patients in a Phase II clinical trial of its “Cand5” drug for the treatment of age related macular degeneration, which trial has been approved by the FDA to be conducted in the United States.
Patient Enrollment. Enrollment numbers are good faith estimates and PPD shall exercise reasonable diligence and efforts to meet such enrollment estimates in accordance with any mutually agreed upon estimated time-lines.
